We advised Bansk Group and its portfolio company PetIQ on the transaction

Davis Polk advised Bansk Group and its portfolio company PetIQ, Inc. on PetIQ’s acquisition of MYOS Corp. Financial terms of the transaction were not disclosed.

Davis Polk previously advised Bansk Group on its acquisition of PetIQ in August 2024.

PetIQ is a leading pet health and wellness company delivering pet parents convenient access to over-the-counter pet medications and wellness products. PetIQ is a portfolio company of Bansk Group, a private investment firm that specializes in building distinctive consumer brands.

MYOS is a bio nutrition company focused on the discovery, development and commercialization of Fortetropin, a proprietary ingredient supporting muscle health, mobility and recovery in both human and companion-animal nutrition.

The Davis Polk corporate team included partners William J. Chudd and Darren M. Schweiger, counsel Rati Ranga and associate Leon Ren. Partner David H. Schnabel provided tax advice. Partner Howard Shelanski provided antitrust and competition advice. Partner Hilary Dengel provided sponsor finance advice. Partner Pritesh P. Shah provided intellectual property advice. Partner Adam Kaminsky provided executive compensation advice. Counsel Michael Comstock provided environmental advice. Members of the Davis Polk team are based in the New York and Washington DC offices.

Copy link to share post